The safety of decitabine as bridging pretreatment regimen before hematopoietic stem cell transplantation in pediatric hematological malignancies
10.3760/cma.j.issn.0578-1426.2018.09.011
- VernacularTitle:地西他滨桥接异基因造血干细胞移植治疗儿童难治性恶性血液病的安全性评估
- Author:
Liyan FAN
1
;
Shaoyan HU
;
Peifang XIAO
;
Jun LU
;
Jie LI
;
Yanhua YAO
;
Jing LING
;
Lingjun KONG
;
Hu LIU
;
Xinni BIAN
Author Information
1. 215003,苏州大学附属儿童医院血液科
- Keywords:
Decitabine;
Allogeneic hematopoietic stem cell transplantation;
Pediatric;
Bridging pretreatment;
Safety
- From:
Chinese Journal of Internal Medicine
2018;57(9):679-682
- CountryChina
- Language:Chinese
-
Abstract:
The safety of decitabine as bridging treatment before allogeneic hematopoietic stem cell transplantation (allo-HSCT) in children with refractory hematological malignancies was evaluated.All 11 cases succeeded in hematopoietic reconstitution.The main adverse reaction was hematological toxicity.Neither did infections occur,nor drug-induced liver damage and renal impairment during decitabine administration.Most cases showed grade Ⅰ-Ⅱ gastrointestinal adverse events.One case was diagnosed as severe acute graft versus host disease and died of intracranial hemorrhage on day 61 after allo-HSCT.The other 10 patients survived.Decitabine bridge is a safe regimen before allo-HSCT in children with refractory hematological malignancies.
